78 results about "Neuroprotective Drugs" patented technology

The invention discloses HGG (Human Gammaglobulin) polypeptide in combination with the tissue specificity of cerebral arterial thrombosis. The invention relates to a method for obtaining the polypeptide. The method comprises the following steps: carrying out in-vivo selection of a mouse MCAO (Middle Cerebral Artery Occlusion) cerebral arterial thrombosis model by adopting an in-vivo phage display peptide library screening technology so as to obtain phage clones in combination with cerebral arterial thrombosis tissue; and randomly selecting the plurality of phage clones to sequence, and authenticating the in-vivo combination specificity of HGG peptide and coded phage clones HGG-M13 thereof. The invention further relates to application of the polypeptide in preparation of a high-sensitivity imaging molecular probe and a targeting delivery neuroprotective drug for cerebral stroke. The polypeptide can be synthesized through an artificial method; the polypeptide is low in molecular weight, high in activity and penetrating power, good in specificity and low in toxicity, and has good tissue targeting of cerebral arterial thrombosis in vivo; and therefore, the polypeptide is applicable to serving as a carrier of the high-sensitivity imaging molecular probe and the targeting delivery neuroprotective drug.

The present invention discloses a chrysotoxine bibenzyl derivative shown as a formula I. R1 represents C=O, CH2, NH, S=O or a covalent bond; R2 represents alkyl, phenyl, substituted phenyl, benzene ring substituted C1-3 alkyl, C5-C6 cycloalkyl, and a pentabasic or hexahydric unsaturated heterocyclic group containing one or more O, S and N. The invention also discloses a simple and efficient preparation method of the chrysotoxine bibenzyl derivative, and application of the derivative to the preparation of neuroprotective drugs and drugs for treating Alzheimer disease. The chrysotoxine 4-O-substituted bibenzyl derivative has significant protective effect on A beta-induced neuronal apoptosis, and is a potential novel chemical entity for the treatment of AD.

The invention relates to a mixed-element terpene compound and an application thereof. The preparation method comprises the following steps: extracting and separating a Durimane Meroterpenoid compoundfrom fermentation liquor of South China Sea soft coral co-epiphytic fungi Alternanthera sp. The mixed-element terpenoid compound can effectively inhibit excitability of mouse primary cerebral cortex neurons, can relieve the stimulation effect of epilepsy inducer 4-aminopyridine on neurons, and can be used for development of neuroprotective drugs. The invention provides a lead compound and a novelactive skeleton for research and development of neuroprotective drugs, and is beneficial to development and utilization of marine medicinal resources.

The invention discloses a new codonopsis pilosula alkynol compound 1 extracted from codonopsis pilosula, a preparation method thereof, a pharmaceutical composition containing a new codonopsis pilosula alkynol compound and application in a neuroprotective drug, especially senile dementia. Pharmacological experiments show that the compound embodies neuroprotection activity and has good neuroprotection activity in a sodium nitroprusside injury primary neuron model and a glutamic acid-induced primary neuron toxicity model. A structural formula of the compound 1 is as shown in the specification.

The invention discloses a tricyclic diterpenoid derivative as shown in a formula (I) and a preparation method of the tricyclic diterpenoid derivative. A series of novel tricyclic diterpenoid derivatives as shown in the formula (I) can be prepared by taking the tricyclic diterpenoid derivative as shown in a formula (5) as a leading compound through such reactions as esterification, amidation, protection, acylation and deprotection. Furthermore, the invention also provides an application of the tricyclic diterpenoid derivative in preparation of neuroprotective drugs.

The invention relates to an application of E-3,4-dihydroxyphenylvinyl sulfoxide represented by the formula I in preparation of nerve protection drugs for treating neurodegenerative diseases, wherein the definitions of each group in the formula I are listed in the description. The invention also relates to a preparation method of E-3,4-dihydroxyphenylvinyl sulfoxide.

Disclosed is the use of 5α-androstane(alkyl)-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord isehemia or hypoxia and has no obvious toxic reaction within effective dose thereof.

The invention discloses a limonin compound as well as a preparation method and a neuroprotective effect thereof, belongs to the field of drugs and in particular relates to a new limonin compound separated from dried whole herb of ruta graveolens as well as a preparation method and a medical application thereof. The compound is reported for the first time, can be obtained by extracting from the dried whole herb of ruta graveolens, separating and purifying and is high in purity. In vitro tests prove that Abeta1-40 toxicity can damage nerve cells and cause large-scale PC12 apoptosis, cell viability is reduced, and apoptosis situation is alleviated after intervention of a compound (I), so that the limonin compound can be further researched and developed into a neuroprotective drug.

The invention discloses an indole N-glycoside compound, an extraction method, and an application in preparing drugs for preventing and treating nervous system diseases. The indole N-glycoside compoundhas a structure represented by a formula (I) in the specification. The indole N-glycoside compound of the invention can effectively protect PC12 cell damages caused by CoCl2, and the result suggeststhat the compound of the invention can be used as a neuroprotective drug.

The invention discloses applications of L-serine or medicinal salts thereof in preparing medicaments used for preventing and treating brain injuries and nerve tissue injuries. The research finds that the L-serine is capable of significantly improving the neural functional grade of a mouse with traumatic brain injuries, reducing brain tissue loss after being injured, alleviating hippocampal neuron neuronal degeneration and necrosis significantly, and improving learning and memory functions. The applications of the L-serine as a nerve protection medicine in treating acute injuries caused by the brain injuries are disclosed for the first time.

The invention relates to the field of medicine synthesis, and discloses a PSD-95 inhibitor. The PSD-95 inhibitor disclosed by the invention is used for preparing a pharmaceutical composition for treating diseases and an application of the pharmaceutical composition in preparing a neuroprotective drug after ischemic brain injury.

The invention discloses a novel limonin compound, a preparation method therefor and a medical application thereof, and belongs to the technical field of medicines. The compound is firstly reported, is a limonin compound with a novel structure, and can be obtained by extracting, separating and purifying young dried fruits of fructus aurantii immaturus. According to an in vitro test, the compound can resist PC12 apoptosis induced by A beta25-32, and can be developed into a neuroprotective drug.

The invention discloses application of a composition containing an MG 53 mutant in preparation of neuroprotective drugs. The research results prove that the MG53 mutant has a prominent neuroprotectiveeffect and can cross the blood-brain barrier, thus being applied to prevention or treatment of multiple neurodegenerative diseases such as ischemic stroke, brain atrophy, senile dementia, multiple system atrophy, brain atrophy, motor neuron diseases, ataxia telangiectasia, spinal muscular atrophy and optic atrophy.

The invention relates to an application of caspofungin in preparation of neuroprotective drugs, and belongs to the field of biological medicines. It is found that the caspofungin is used for inhibiting or treating neuronal or axonal degeneration, is especially used for treating vision-related neurodegeneration and nervous system diseases, more especially has the protective effect on the vision-related neurodegeneration, can remarkably relieve retinal ganglion cell and axonal damage, and has the nerve cell protection function.

The invention belongs to the technical fields of tree secondary metabolism active ingredients and natural medicines, and particularly relates to a method for preparing macranthoin G by taking medicinal tree seed eucommia ulmoides as a raw material, and use of the macranthoin G in preparation of a neuroprotective medicine. The macranthoin G is prepared from eucommia ulmoides tree plant materials as raw materials in manners of drawing, extracting and separating. Themacranthoin G is simple in preparation technology, low in cost, short in cycle and high in yield. An experiment proves that themacranthoin G plays a significant protection role on a model cell injury, and indicates that the macranthoin G can be applied to preparation of the neuroprotective medicine, so as to prevent and treat various neurodegenerative diseases.

The invention discloses a novel quinolone alkaloid compound 1 extracted from Evodia rutaecarpa, a preparation method of the novel quinolone alkaloid compound, a pharmaceutical composition containing the novel quinolone alkaloid compound and application thereof to neuroprotective drugs, in particular to drugs for treating the Alzheimer's disease. Pharmacological experiments show that neuroprotective activity is embodied in the novel quinolone alkaloid compound, in other words, the novel quinolone alkaloid compound has excellent neuroprotective activity in a sodium-nitroprusside-induced primary neuron damage model and a glutamate-induced primary neuron toxicity model.